Orchestra BioMed (NASDAQ: OBIO) — Perfil da empresa, notícias e dados financeiros
Orchestra BioMed develops therapeutic devices for healthcare challenges like cardiac issues and chronic pain.
Orchestra BioMed
Orchestra BioMed (NASDAQ:OBIO) is a biomedical company focused on developing innovative solutions to address some of the world's most pressing healthcare challenges. The company's operations span the creation and commercialization of therapeutic devices and technologies aimed at treating conditions like cardiac issues and chronic pain, among others. Orchestra BioMed's projects are distinguished by a partnership model that seeks to collaborate with leading healthcare organizations to accelerate the development and delivery of its products. This approach aims to enhance accessibility and adoption of their technologies in the global market. The company's primary objectives revolve around improving patient outcomes, reducing healthcare costs, and achieving significant milestones that advance their products through clinical trials towards commercialization.
Resumo
Operações
Produtos e/ou serviços de Orchestra BioMed
- BackBeat Cardiac Neuromodulation Therapy (CNT) offering a unique approach to hypertension and heart failure management by modulating the autonomic nervous system to reduce blood pressure.
- Virtue Sirolimus-Eluting Balloon, a novel drug delivery system designed for the treatment of coronary and peripheral artery diseases that combines mechanical dilatation and local drug delivery.
- Motiv BP Monitoring System, an advanced technology for tracking blood pressure that offers patients a more user-friendly and accurate way to monitor their hypertension.
- Bioabsorbable Scaffold Systems that provide structural support to arteries with the advantage of being resorbed by the body, potentially reducing long-term complications.
equipe executiva do Orchestra BioMed
- David P. HochmanFounder, Chairman of the Board of Directors & CEO
- Darren R. ShermanFounder, President, COO & Director
- Andrew Lawrence TaylorChief Financial Officer
- William Reed LittleExecutive Vice President of Corporate Development & Strategy
- Lisa DanielsVice President of Human Resources
- Yuval Hay MikaGM & CTO of Bioelectronic Therapies
- Hans-Peter StollSenior VP & Medical Director
- Avraham Matityahu FischerSenior Vice President of Medical Affairs & Innovation
- Bob LaughnerSenior Vice President of Regulatory & Quality
- Juan LorenzoSenior Vice President of Product Development
Principais indicadores financeiros
Resultados divulgados pela Orchestra BioMed, em USD.
- Cap. de mercado
- 347,4 mi
- Receita (TTM)
- 32 mi
- P/L
- —
- LPA (diluído, TTM)
- -0.9
- Dividend yield
- —
- Margem de lucro
- -184.6%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 33,5 mi | -51,8 mi | -52,7 mi | |
| 2,6 mi | -64,3 mi | -61 mi | |
| 2,8 mi | -51,5 mi | -49,1 mi | |
| 3,5 mi | -32,7 mi | -33,6 mi |